Taken together, our data provide novel preclinical evidence that combined pharmacological targeting of the IGF2BP1-EZH2-MYC axis at various levels offers a promising, yet unexplored, strategy for the therapy of neuroendocrine tumors which warrants further validation in clinical studies. The gene discussed is MYC; the disease is neuroendocrine neoplasm.